Literature DB >> 7751637

Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

P F Robbins1, M el-Gamil, Y F Li, S L Topalian, L Rivoltini, K Sakaguchi, E Appella, Y Kawakami, S A Rosenberg.   

Abstract

The role of tumor-specific T cells in mediating the regression of metastatic melanoma has been suggested by the clinical response of patients to treatment with tumor-infiltrating lymphocytes (TIL). A number of Ags recognized by class I-restricted melanoma-specific T cells have recently been isolated, raising the hope that this will lead to the development of improved therapies. In this study, we report the cloning of a tumor Ag recognized by T cells from melanoma patient 888. Previously, we reported that TIL 888, grown from the tumor of this patient, recognized tyrosinase in an HLA-A24-restricted fashion. This line, when infused into the autologous patient, resulted in complete regression of multiple metastases. Three years later, a second TIL line, TIL 1290, was isolated from a recurrent pelvic tumor. Infusion of a mixture of TIL 888 and TIL 1290 cell lines into the patient resulted in complete regression of a residual abdominal mass and the patient remains disease-free 2 yr later. The TIL 1290 cell line, which recognized melanoma in an HLA-A24-restricted manner, failed to recognize tyrosinase. TIL 1290 was then used to screen an 888 melanoma cDNA library, and an Ag was isolated that did not correspond to any found in sequence databases. This gene, termed p15, was found to be expressed in a variety of normal tissues, and a peptide epitope recognized by TIL 1290 was found to represent the product of an nonmutated gene. Screening of additional cDNA pools resulted in the isolation of a second clone which stimulated TIL 1290. This clone also appeared to represent a transcript of the p15 gene, indicating that this gene may encode the predominant Ag recognized by TIL 1290.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7751637

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

2.  Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients.

Authors:  Sergiusz Markowicz; Zbigniew I Nowecki; Piotr Rutkowski; Andrzej W Lipkowski; Marzena Biernacka; Anna Jakubowska-Mucka; Tomasz Switaj; Aleksandra Misicka; Henryk Skurzak; Hanna Polowniak-Pracka; Jan Walewski
Journal:  Med Oncol       Date:  2012-12       Impact factor: 3.064

3.  NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.

Authors:  Frits van Rhee; Susann M Szmania; Fenghuang Zhan; Sushil K Gupta; Mindy Pomtree; Pei Lin; Ramesh B Batchu; Amberly Moreno; Guilio Spagnoli; John Shaughnessy; Guido Tricot
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

Review 4.  T-cell recognition of self peptides as tumor rejection antigens.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

5.  In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.

Authors:  M Hishii; D Andrews; L A Boyle; J T Wong; F Pandolfi; P J van den Elsen; J T Kurnick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 6.  Direct identification of tumor-associated peptide antigens.

Authors:  V H Engelhard
Journal:  Springer Semin Immunopathol       Date:  1996

Review 7.  Progress in the development of immunotherapy for the treatment of patients with cancer.

Authors:  S A Rosenberg
Journal:  J Intern Med       Date:  2001-12       Impact factor: 8.989

8.  Developing effective tumor vaccines: basis, challenges and perspectives.

Authors:  Qingwen Xu; Weifeng Chen
Journal:  Front Med China       Date:  2007-02-01

9.  Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402.

Authors:  Toshiyuki Baba; Marimo Sato-Matsushita; Akira Kanamoto; Akihiko Itoh; Naoki Oyaizu; Yusuke Inoue; Yutaka Kawakami; Hideaki Tahara
Journal:  J Transl Med       Date:  2010-09-16       Impact factor: 5.531

10.  Regulation of mitochondrial ribosomal protein S29 (MRPS29) expression by a 5'-upstream open reading frame.

Authors:  Min-Joon Han; Daniel T Chiu; Emine C Koc
Journal:  Mitochondrion       Date:  2010-01-14       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.